Jonathan Matz, MD
Allergy · White Marsh, MDNPI 1013966100
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $103,158 of the $146,643 with a category attached, or 70.3%. 49 manufacturers reported payments, led by Cipla USA Inc. at 52.8% of the total. Reporting peaked in 2024 at $89,930 and has fallen 91.3% since, to $7,848 in 2025.
Across 1,414 payments — averaging $103.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cipla USA Inc.$77K
- AstraZeneca$16K
- Sanofi$10K
- Regeneron Healthcare Solutions, Inc.$9K
- Novartis$8K
- Genentech USA, Inc.$7K
- plus $20K from 43 others
Across 657 payments — averaging $9092.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$2.9M
- Chiesi USA, Inc.$528K
- Teva Pharmaceuticals USA, Inc.$509K
- Novartis$370K
- Cipla USA Inc.$346K
- Siemens Medical Solutions USA, Inc.$294K
- plus $1.1M from 14 others
What the payments were for
- Consulting fees$6,2884%
- Speaking & faculty fees$103,15870%
- Travel & lodging$5,5284%
- Food & beverage$31,29321%
- Education$3770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$146,643 in reported general payments places this provider in the 85th percentile of 29 allergy providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 77 | $320,597 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $112,499 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 14 | $96,313 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 89 | $84,298 |
| Breo ElliptaFluticasone/Vilanterol | 47 | $38,036 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 47 | $30,410 |
| Advair HfaFluticasone Propion/Salmeterol | 40 | $16,408 |
| Arnuity ElliptaFluticasone Furoate | 51 | $16,254 |
| Spiriva RespimatTiotropium Bromide | 19 | $15,697 |
| Epinephrine | 70 | $15,510 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $10,229 |
| DuleraMometasone/Formoterol | 20 | $10,019 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 51 | $8,624 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $8,497 |
| Montelukast Sodium | 384 | $7,378 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta | $4,030 | $147,085201 claims |
| CSL BehringHizentra | $1,842 | $112,49912 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $1,657 | $96,31314 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $15,953 | $40,63968 claims |
| Boehringer IngelheimSpiriva Respimat | $188 | $15,69719 claims |
| Hikma Pharmaceuticals USAEpinephrine | $17 | $15,51070 claims |
| MerckDulera | $37 | $10,01920 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler, Qnasl | $209 | $9,88828 claims |
| Covis Pharma GmbHAlvesco | $21 | $3,79415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 29 allergy providers in Maryland.
Other allergy in White Marsh
- Huamin LiWheaton$576K
- David GoldenBaltimore$197K
- Jody TverskyBaltimore$175K
- Sarbjit SainiBaltimore$174K
- Newton AdkinsonBaltimore$61K
- Brett CoonsJb Andrews$49K
- Peter CreticosBaltimore$22K
- David SchwartzBethesda$15K
- Asek MakiaMitchellville$11K
- Leo ShueRockville$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.